TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Azithromycin in Treatment of Bronchiectasis
Brief Summary: Bronchiectasis is a chronic lung condition characterised primarily by dilatation of the airways. Only a small number of clinical studies have been conducted investigating the use of macrolides to treat non-cystic fibrosis bronchiectasis. The purpose of this study is to determine the efficacy of 12 weeks treatment with azithromycin in adult patients with non-cystic fibrosis bronchiectasis.


Options:
A: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
B: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
C: Intervention Type: DRUG; Name: Intravenous Clarithromycin; Assigned to Arm(s): N/A
D: Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
Brief Summary: Over 60% of cancers occur in older persons, and the number of older persons with cancer is expected to grow as the population ages. Oncology clinical trials have traditionally excluded older patients with advanced cancer and chronic health conditions. In this context, where data is limited and risk from treatment is high, older patients with advanced cancer and their caregivers must understand how cancer treatment can affect quality of life in light of underlying health status. Better communication about age-related health conditions between oncologists, older patients with advanced cancer, and their caregivers may improve decision-making for cancer treatment and quality of life. A geriatric assessment (GA), a validated set of patient-centered outcomes, has been shown to identify concerns (e.g., function, cognition) important to older persons with cancer and their caregivers. In this cluster randomized clinical trial we examined whether providing a web-generated GA summary with targeted recommendations to older patients with advanced cancer, their caregivers, and their oncologists can improve communication about age-related concerns that could affect efficacy and tolerance of cancer treatment. We also determined whether the intervention improves patient-reported quality of life and patient and caregiver satisfaction.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training and coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication training and coaching; Assigned to Arm(s): Intervention
B: Arm Label: Arm I: Geriatric Assessment Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Geriatric Assessment Summary, Behavioral: Geriatric Assessment Targeted Recommendations, Behavioral: Geriatric Assessment (GA) | Arm Label: Arm II: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Geriatric Assessment (GA) | Intervention Type: BEHAVIORAL; Name: Geriatric Assessment Summary; Assigned to Arm(s): Arm I: Geriatric Assessment Intervention | Intervention Type: BEHAVIORAL; Name: Geriatric Assessment Targeted Recommendations; Assigned to Arm(s): Arm I: Geriatric Assessment Intervention | Intervention Type: BEHAVIORAL; Name: Geriatric Assessment (GA); Assigned to Arm(s): Arm I: Geriatric Assessment Intervention, Arm II: Usual Care
C: Arm Label: Trained Clinicians; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Non-trained Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non-volunteer Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Trained Clinicians
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ACTIVE; Type: EXPERIMENTAL; Interventions: Behavioral: ACTIVE | Intervention Type: BEHAVIORAL; Name: ACTIVE; Assigned to Arm(s): ACTIVE

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Twice-Weekly Intense Aerobic Exercise in Early Subacute Stroke: A Randomized Controlled Trial.
Brief Summary: The purpose of this study was to investigate the effects of early intensive aerobic exercise regarding aerobic capacity, gait and balance, Health Related Quality of Life and participation.


Options:
A: Arm Label: Early Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early locomotor training program | Arm Label: Late Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Late locomotor training program | Arm Label: Early Home Exercise Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Exercise Program | Intervention Type: BEHAVIORAL; Name: Early locomotor training program; Assigned to Arm(s): Early Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Late locomotor training program; Assigned to Arm(s): Late Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Home Exercise Program; Assigned to Arm(s): Early Home Exercise Program
B: Arm Label: Exercise recommendation; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: Aerobic exercise; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise, Exercise recommendation
C: Arm Label: ASAP; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: DEUCC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-Equivalent Usual & Customary Care - DEUCC | Arm Label: UCC; Type: OTHER; Interventions: Behavioral: Usual and Customary Care - UCC | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): ASAP | Intervention Type: BEHAVIORAL; Name: Dose-Equivalent Usual & Customary Care - DEUCC; Assigned to Arm(s): DEUCC | Intervention Type: BEHAVIORAL; Name: Usual and Customary Care - UCC; Assigned to Arm(s): UCC
D: Arm Label: Tai chi program via Telerehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi based exercise program | Arm Label: Tai chi program via home visits; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tai Chi based exercise program | Intervention Type: BEHAVIORAL; Name: Tai Chi based exercise program; Assigned to Arm(s): Tai chi program via Telerehabilitation, Tai chi program via home visits

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Twice-Weekly Intense Aerobic Exercise in Early Subacute Stroke: A Randomized Controlled Trial.
Brief Summary: The purpose of this study was to investigate the effects of early intensive aerobic exercise regarding aerobic capacity, gait and balance, Health Related Quality of Life and participation.


Options:
A: Arm Label: Flywheel leg-press resistance exercise; Type: EXPERIMENTAL; Interventions: Other: Flywheel leg-press resistance exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Flywheel leg-press resistance exercise; Assigned to Arm(s): Flywheel leg-press resistance exercise
B: Arm Label: Exercise recommendation; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: Aerobic exercise; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise, Exercise recommendation
C: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
D: Arm Label: FAST+SAM; Type: EXPERIMENTAL; Interventions: Behavioral: FAST+SAM | Arm Label: FAST alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: FAST alone | Arm Label: SAM alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SAM alone | Intervention Type: BEHAVIORAL; Name: FAST alone; Assigned to Arm(s): FAST alone | Intervention Type: BEHAVIORAL; Name: FAST+SAM; Assigned to Arm(s): FAST+SAM | Intervention Type: BEHAVIORAL; Name: SAM alone; Assigned to Arm(s): SAM alone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124)
Brief Summary: The primary objective of this study is to determine the long-term safety and tolerability of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) who completed participation in the double-blind study PTC124-GD-009-CF (NCT00803205), as assessed by adverse events and laboratory abnormalities. The secondary objective of this study includes the assessment of the efficacy of ataluren, as measured by forced expiratory volume in 1 second (FEV1) and pulmonary exacerbation rate, and other safety parameters (for example, 12-lead electrocardiogram \[ECG\] measurements, vital signs).


Options:
A: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: N6022; Type: EXPERIMENTAL; Interventions: Drug: N6022 | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: N6022; Assigned to Arm(s): N6022 | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Normal saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Brief Summary: This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. The results of Cohort 1 are reported separately (NCT02951767). Cohort 2 (reported here) will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen. Participants in both cohorts will be given a 1200 milligrams (mg) intravenous (IV) dose of atezolizumab on Day 1 of 21-day cycles. Treatment of participants in Cohort 1 will continue until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or unmanageable toxicity. Treatment of participants in Cohort 2 will continue until loss of clinical benefit or unmanageable toxicity.


Options:
A: Arm Label: Control Arm A; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Experimental Arm B; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control Arm A | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Experimental Arm B
B: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab
C: Arm Label: Cohort 2: Participants With Second-line or Beyond Treatments; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Cohort 2: Participants With Second-line or Beyond Treatments
D: Arm Label: Atezolizumab+Gemcitabine+Carboplatin/Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Drug: Carboplatin, Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Placebo+Gemcitabine+Carboplatin/Cisplatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Other: Placebo, Drug: Cisplatin | Arm Label: Atezolizumab Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab Monotherapy, Atezolizumab+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Atezolizumab+Gemcitabine+Carboplatin/Cisplatin, Placebo+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Atezolizumab+Gemcitabine+Carboplatin/Cisplatin, Placebo+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo+Gemcitabine+Carboplatin/Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Atezolizumab+Gemcitabine+Carboplatin/Cisplatin, Placebo+Gemcitabine+Carboplatin/Cisplatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Descending Age Double-blinded Randomized Placebo-controlled Dose Escalation Study to Examine the Safety Reactogenicity Tolerability & Immunogenicity of the P2-VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers & Infants
Brief Summary: This is is a study of a parenteral rotavirus vaccine (P2-VP8 subunit rotavirus vaccine). The study will examine the safety and immunogenicity of this vaccine first in healthy South African toddlers. If the safety profile is deemed appropriate, the study will continue to explore the safety and immunogenicity of the vaccine in healthy South African infants.

The primary safety hypothesis is that the P2-VP8 subunit rotavirus vaccine is safe and well-tolerated in healthy toddlers and infants. The primary immunogenicity hypothesis is that the P2-VP8 subunit rotavirus vaccine is immunogenic in infant participants and will induce an immune response in at least 80% of participants in at least one of the study groups.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: OTHER; Interventions: Biological: Rotateq vaccine | Intervention Type: BIOLOGICAL; Name: Rotateq vaccine; Assigned to Arm(s): 1
C: Arm Label: Cohort A P2-VP8 30 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort A P2-VP8 60 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort B P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Arm Label: Cohort B placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort B P2-VP8 30mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort B1 P2-VP8 60mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort A P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 10mcg; Assigned to Arm(s): Cohort A P2-VP8 10mcg, Cohort B P2-VP8 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 30 mcg; Assigned to Arm(s): Cohort A P2-VP8 30 mcg, Cohort B P2-VP8 30mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 60mcg; Assigned to Arm(s): Cohort A P2-VP8 60 mcg, Cohort B1 P2-VP8 60mcg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort B placebo
D: Arm Label: Vaccine Arm; Type: EXPERIMENTAL; Interventions: Biological: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV) | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV); Assigned to Arm(s): Vaccine Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Prevention of Childhood Obesity: an Active Pregnancy
Brief Summary: The main aim of this study was to examine the effect of a supervised physical exercise program on the prevention of childhood obesity and its impact on the motor development of the offspring.


Options:
A: Arm Label: Rééducation; Type: EXPERIMENTAL; Interventions: Other: Pelvic floor muscle training with physiotherapist, Other: Written information about kegel exercises | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Written information about kegel exercises | Intervention Type: OTHER; Name: Pelvic floor muscle training with physiotherapist; Assigned to Arm(s): Rééducation | Intervention Type: OTHER; Name: Written information about kegel exercises; Assigned to Arm(s): Control, Rééducation
B: Arm Label: Postpartum pelvic floor muscle training; Type: EXPERIMENTAL; Interventions: Other: Postpartum pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Postpartum pelvic floor muscle training; Assigned to Arm(s): Postpartum pelvic floor muscle training
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: A supervised physical exercise program | Intervention Type: BEHAVIORAL; Name: A supervised physical exercise program; Assigned to Arm(s): Exercise group
D: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: a Controlled, Randomized Study Evaluating the Immediate Effect of One tDCS Session on Quadriceps Strength in Hemiparetic Patients.
Brief Summary: Previous studies show that one session of tDCS allow to improve muscle strength in hemiparetic patients in anodal condition. We test a new electrods configuration : a anodale stimulation opposite to the cortical representation area of the injured hemisphere and a simultaneous stimulation opposite to the homonyme the cortical representation area of the healthy hemisphere. This approach seems to be the best relevant electrods configuration in order to restore the inter-hemispheric balance.

We hypothesis that one session of tDCS with this electrods configuration allow to improve paretic quadriceps strength in hemiparetic patients after stroke.


Options:
A: Arm Label: hemiplegic patient; Type: EXPERIMENTAL; Interventions: Device: transcranial Direct current stimulation | Arm Label: patient control; Type: SHAM_COMPARATOR; Interventions: Device: transcranial Direct current stimulation | Intervention Type: DEVICE; Name: transcranial Direct current stimulation; Assigned to Arm(s): hemiplegic patient, patient control
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HEP-OKS; Type: EXPERIMENTAL; Interventions: Behavioral: hemifield eye patching (HEP) + optokinetic stimulation (OKS) | Intervention Type: BEHAVIORAL; Name: hemifield eye patching (HEP) + optokinetic stimulation (OKS); Assigned to Arm(s): HEP-OKS
C: Arm Label: Active tdcs / CIMT; Type: EXPERIMENTAL; Interventions: Device: Transcranial direct current stimulation, Behavioral: Constraint-Induced Movement Therapy | Arm Label: Sham stimulation / CIMT; Type: SHAM_COMPARATOR; Interventions: Behavioral: Constraint-Induced Movement Therapy, Other: Placebo | Intervention Type: DEVICE; Name: Transcranial direct current stimulation; Assigned to Arm(s): Active tdcs / CIMT | Intervention Type: BEHAVIORAL; Name: Constraint-Induced Movement Therapy; Assigned to Arm(s): Active tdcs / CIMT, Sham stimulation / CIMT | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Sham stimulation / CIMT
D: Arm Label: real tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: tDCS | Arm Label: no stimulation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): real tDCS, sham tDCS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Brief Summary: The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of study.


Options:
A: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
B: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
C: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
D: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A

Answer: D